A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: A study of the SAA Working Party of the European Group for Blood and Marrow Transplantation

Blood

Volumn 117, Issue 17, 2011, Pages 4434-4441

  Tichelli, André ^a   Schrezenmeier, Hubert ^b   Socié, Gérard ^c   Marsh, Judith ^d   Bacigalupo, Andrea ^e   Dührsen, Ulrich ^f   Franzke, Anke ^g   Hallek, Michael ^h   Thiel, Eckhard ⁱ   Wilhelm, Martin ^j   Höchsmann, Britta ^b   Barrois, Alain ^k   Champion, Kim ^l   Passweg, Jakob R ^m  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c SAINT LOUIS HOSPITAL   (France)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e Ospedalo San Martino   (Italy)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j KLINIKUM NÜRNBERG   (Germany)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l GUY S HOSPITAL   (United Kingdom)

^m GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; OVERALL SURVIVAL; POST HOC ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SCHOOL CHILD; SERUM SICKNESS;

EID: 79955951071     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-304071     Document Type: Article

References (27)

1. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101(4):1236-1242. (Pubitemid 36182490)
2. Hattori M, Terasawa T, Tsushita K, et al. The status of antithymocyte globulin therapy for adult patients in Japan: retrospective analysis of a nationwide survey. Int J Hematol. 2008;87(1):48-55.
3. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11-18. (Pubitemid 46232653)
4. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144(2):206-216.
5. Brodsky RA, Chen AR, Dorr D, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010;115(11):2136-2141.
6. Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and singlelineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol. 2010; 148(5):791-796.
7. Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009;94(3):348-354.
8. Marsh JC, Socie G, Schrezenmeier H, et al. Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet. 1994;344(8916):172-173.
9. Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002;119(4):1075-1082. (Pubitemid 35463836)
10. Gordon-Smith EC, Yandle A, Milne A, et al. Randomised placebo controlled study of RH-GM-CSF following ALG in the treatment of aplastic anaemia. Bone Marrow Transplant. 1991;7(suppl 2): 78-80.
11. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96(6): 2049-2054.
12. Shao Z, Chu Y, Zhang Y, Chen G, Zheng Y. Treatment of severe aplastic anemia with an immunosuppressive agent plus recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin. Am J Hematol. 1998;59(3): 185-191. (Pubitemid 28485498)
13. Teramura M, Kimura A, Iwase S, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood. 2007;110(6):1756-1761. (Pubitemid 47443885)
14. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol. 2006;34(7):826-831. (Pubitemid 43949184)
15. Fuhrer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106(6):2102-2104. (Pubitemid 41291726)
16. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48(1):63-70.
17. Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988;70(2):177-182.
18. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982;1(2):121-129. (Pubitemid 13146129)
19. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95(6):1931-1934.
20. Bacigalupo A, Socie' G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica. 2010; 95(6):976-982.
21. Mao P, Zhu Z, Wang H, et al. Sustained and stable hematopoietic donor-recipient mixed chimerism after unrelated cord blood transplantation for adult patients with severe aplastic anemia. Eur J Haematol. 2005;75(5):430-435. (Pubitemid 41445084)
22. Marsh J. Making therapeutic decisions in adults with aplastic anemia. Hematology Am Soc Hematol Educ Program. 2006:78-85.
23. Gurion R, Gafter-Gvili A, Paul M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009; 94(5):712-719.
24. Bacigalupo A. Aplastic anemia: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2007:23-28.
25. Locasciulli A, Arcese W, Locatelli F, Di BE, Bacigalupo A. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Italian Aplastic Anaemia Study Group. Lancet. 2001;357(9249):43-44. (Pubitemid 32056504)
26. Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2007;109(7):2794-2796. (Pubitemid 46482073)
27. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90(3): 1009-1013. (Pubitemid 27314134)